Clinicopathological characteristics, evolution, and treatment outcomes of hormone receptor-negative/HER2-low metastatic breast cancer: a pooled analysis of individual patient data from three prospective clinical trials
In mTNBC patients, those with HER2-low status had similar responses to platinum-based chemotherapy as HER2-0 patients. There was significant discordance in HER2 status between primary and metastatic lesions. Patients with discordant HER2 status had better responses to platinum-based chemotherapy. Therefore, for patients with HER2-0 primary lesions, re-evaluation of HER2 status in metastatic lesions through biopsy may offer new treatment opportunities.
Authors
- Shihui Hu
- Biyun Wang (ORCID: https://orcid.org/0000-0002-7829-1544)
- Yannan Zhao (ORCID: https://orcid.org/0000-0003-1353-8443)
- Leiping Wang (ORCID: https://orcid.org/0000-0002-0605-1621)
- Shuhui You (ORCID: https://orcid.org/0009-0003-5002-7391)
- Chengcheng Gong (ORCID: https://orcid.org/0000-0002-5429-0248)
- Jun Cao (ORCID: https://orcid.org/0000-0002-5591-2299)
- Jian Zhang (ORCID: https://orcid.org/0000-0001-8338-9426)
- Xichun Hu (ORCID: https://orcid.org/0000-0002-3488-6394)
- Yizhao Xie
Institutions
- Shanghai Medical College of Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2024-11-21
- DOI
- https://doi.org/10.3389/fendo.2024.1449278
- Citations
- 3
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- Shanghai Anti-Cancer Association
- Beijing Xisike Clinical Oncology Research Foundation